Objective:To determine if acute treatment with aripiprazole (APZ) would be superior to treatment with placebo in reducing dysfunctional symptoms of elevated mood and/or irritability in symptomatic children and adolescents...
Lundbeck and Otsuka Pharmaceutical Co announced Abilify Maintena (aripiprazole) for extended-release injectable suspension was approved by the FDA for the...
Objective: To determine the efficacy and safety of tDCS as an add-on treatment for bipolar depression.
Alkermes plc announced positive topline results from a randomized, double-blind, placebo-controlled phase III clinical trial of aripiprazole lauroxil in patients...
Objective: This study aimed to evaluate the efficacy and adverse events of vortioxetine for Chinese patients with major depressive disorder (MDD) over 10 weeks.
Aripiprazole is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1). Aripiprazole is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).